Tags : Renal Cell Carcinoma

Merck’s MK-6482 Receives the US FDA’s Breakthrough Therapy Designation to

Shots: The designation is based on P-II study evaluating MK-6482 in patients with VHL-associated RCC with nonmetastatic RCC tumors >3cms in size, unless immediate surgery is required The FDA’s BT designation is granted to expedite the development and review of medicines that are intended to treat serious or life-threatening conditions and have demonstrated preliminary clinical […]Read More

Exelixis Initiates P-III COSMIC-313 Study of Triple Combination Therapy for

Shots: The P-III COSMIC-313 study involves assessing of Cabometyx (cabozantinib) + Opdivo (nivolumab) + Yervoy (ipilimumab) vs nivolumab+ ipilimumab + PBO in 676 patients in the ratio (1:1) with previously untreated advanced RCC across 150 sites globally The P-III COSMIC-313 study follows ongoing P-Ib study assessing cabozantinib + nivolumab with/without ipilimumab in patients with advanced […]Read More

AVEO Oncology Reports Results of Fotivda (tivozanib) in P-III TIVO-3

Shots: The P-III TIVO-3 study involves assessing of Fotivda (tivozanib) vs sorafenib in 350 patients with refractory advanced or metastatic renal cell carcinoma (RCC) P-III TIVO-3 results: 44% improvement in mPFS; 26% reduction in the risk of progression or death; mPFS (5.6 vs 3.9 mos.); ORR (18% vs 8%), presented at ASCO Genitourinary Cancers Symposium, […]Read More